HUGO-Ab™ Mouse Models

HUmanized Genomic Ortholog for Antibody Development
Revolutionize Your Therapeutic Antibody Discovery with our Breakthrough Fully Human Antibody Mouse Model
  • Humanization of Immunoglobulin Variable Regions
  • Robust Immune Response
  • High-Affinity Fully Human Antibodies
  • Rich Diversity of Fully Human Antibody Sequences
  • Optimized for Antibody Drug Discovery

Fully human antibodies are revolutionizing the immunotherapeutic landscape for cancer and autoimmune diseases, thanks to their superior affinity, specificity, and minimized side effects. To meet the rising demand for innovative in vivo models for fully human antibody discovery and drug development, Cyagen has leveraged our suite of cutting-edge technologies to bring you the HUGO-Ab™ mice.

HUGO-Ab™ Mouse Model: Scheme of Humanization Strategy of Heavy Chain and Light Chain

HUGO-Ab™ Humanized Antibody Discovery Platform

◆ Immunization
  • Protein Immunization
  • DNA & RNA Immunization
  • Cell Immunization
◆ Antibody Discovery
  • Hybridoma Screening
  • Phage Display
◆ Antibody Engineering
  • Affinity Maturation
  • Fc Engineering
◆ Antibody Discovery
  • Hybridoma Screening
  • Phage Display
◆ Antibody Functional Pharmacologic Evaluation
  • In Vitro Efficacy
  • In Vivo Efficacy

Validation Data for HUGO-Ab™ Mice

◆  Efficient Immune Response to Antigens

☛ High Titer Response Against PD-L1

Experience the pinnacle of fully human antibody research innovation with HUGO-Ab™. Our mice consistently demonstrate antibody reactivity at serum dilutions of 1:256,000 post-immunization, indicating a robust immune response equivalent to that of wild-type (WT) mice. This showcases strong immune response in HUGO-Ab™ mice.

Figure 1: Serum Titer Measurement for PD-L1 Immunization

HUGO-119, HUGO-131, and HUGO-135 are HUGO-Ab™ fully humanized antibody mice; WT-C57-1, WT-C57-2 are wild-type C57BL/6NCya mice; WT-Ba-1, WT-Ba-2 are wild-type BALB/c mice.

☛ Diversity in Fully Human Antibodies

Antibody sequencing of HUGO-Ab™ mice immunized with antigens reveals a substantial diversity in the fully human antibody repertoire, in both heavy and light chain sequences.

Figure 2: Fully Human Heavy and Light Chain Antibody Sequences

☛ Achieving High-Affinity Antibody Sequences

Figure 3: In vitro Analysis of anti-PDL1 Candidate Molecules

HU001-01 and HU001-02 are candidate molecules from HUGO-Ab™ mice; Atezolizumab is the benchmark antibody.

Figure 4: In vitro Analysis of anti-B7H3 Candidate Molecules

HU002-01 and HU002-02 are candidate molecules from HUGO-Ab™ mice; Ombortamab is the benchmark antibody.

◆ IGH V(D)J Gene Rearrangement Frequency

The frequency of IGH and IGK V(D)J gene rearrangement in HUGO-Ab™ mice closely matches the frequency of IGH and IGK V(D)J Germline gene rearrangement in humans.

Figure 5: Comparison of IGH & IGK V(D)J Gene Rearrangement Frequency in HUGO-Ab™ Mice

◆ B Cell Development in HUGO-Ab™ Mice

Compared to normal wild-type mice, the development of B cells in the immune system of HUGO-Ab™ mice shows no abnormalities.

Figure 6. Comparison of B Cell Development Levels in the Immune System of HUGO-Ab™ Mice

Why Choose HUGO-Ab™?

◆ Advanced Humanization
Humanizing the whole heavy and light chain V(D)J variable regions, offering greater genetic diversity and low immunogenicity for antibody development.

◆ Rich Sequence Diversity
The fully humanized variable region V(D)J recombination generates a diverse antibody repertoire, ensuring an immune response similar to that of wild mice when exposed to antigens.

◆ High-Affinity Antibody Screening
Capable of producing high-affinity antibodies at the picomolar level, matching the binding and blocking affinity of benchmark antibodies.

◆ Flexible Business Models
Open to various collaborative efforts including licensing and co-development, supporting flexible partnership opportunities.

Based on the HUGO-Ab™ humanized antibody mouse model and antibody discovery platform, we look forward to collaborating with researchers to fully leverage the drug-like properties optimized in the mouse model, and to advance the development of human antibodies.